$2.34
0.00% day before yesterday
Nasdaq, Aug 30, 01:57 am CET
ISIN
US45256X1037
Symbol
IBRX

ImmunityBio Inc Target price 2025 - Analyst rating & recommendation

ImmunityBio Inc Classifications & Recommendation:

Buy
91%
Hold
9%

ImmunityBio Inc Price Target

Target Price $8.16
Price $2.34
Potential
Number of Estimates 7
7 Analysts have issued a price target ImmunityBio Inc 2026 . The average ImmunityBio Inc target price is $8.16. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 10 Analysts recommend ImmunityBio Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the ImmunityBio Inc stock has an average upside potential 2026 of . Most analysts recommend the ImmunityBio Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 14.75 107.63
2,279.03% 629.69%
Net Margin -2,803.80% -416.27%
97.02% 85.15%

7 Analysts have issued a sales forecast ImmunityBio Inc 2025 . The average ImmunityBio Inc sales estimate is

$108m
Unlock
. This is
90.16% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$115m 102.95%
Unlock
, the lowest is
$98.4m 73.91%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $14.8m 2,279.03%
2025
$108m 629.69%
Unlock
2026
$226m 109.91%
Unlock
2027
$566m 150.39%
Unlock
2028
$1.0b 78.01%
Unlock
2029
$2.0b 98.11%
Unlock
2030
$3.5b 75.39%
Unlock
2031
$6.7b 91.60%
Unlock
2032
$9.4b 40.83%
Unlock

7 ImmunityBio Inc Analysts have issued a net profit forecast 2025. The average ImmunityBio Inc net profit estimate is

$-448m
Unlock
. This is
22.05% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-394m 7.34%
Unlock
, the lowest is
$-535m 45.72%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-414m 29.09%
2025
$-448m 8.33%
Unlock
2026
$-310m 30.87%
Unlock
2027
$-52.2m 83.15%
Unlock
2028
$309m 691.65%
Unlock
2029
$1.0b 226.75%
Unlock
2030
$2.1b 106.90%
Unlock
2031
$4.4b 109.37%
Unlock
2032
$6.0b 37.01%
Unlock

Net Margin

2024 -2,803.80% 97.02%
2025
-416.27% 85.15%
Unlock
2026
-137.08% 67.07%
Unlock
2027
-9.23% 93.27%
Unlock
2028
30.67% 432.29%
Unlock
2029
50.58% 64.92%
Unlock
2030
59.67% 17.97%
Unlock
2031
65.21% 9.28%
Unlock
2032
63.44% 2.71%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.59 -0.53
48.70% 10.17%
P/E negative
EV/Sales 26.55

7 Analysts have issued a ImmunityBio Inc forecast for earnings per share. The average ImmunityBio Inc EPS is

$-0.53
Unlock
. This is
29.27% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.46 12.20%
Unlock
, the lowest is
$-0.63 53.66%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.59 48.70%
2025
$-0.53 10.17%
Unlock
2026
$-0.36 32.08%
Unlock
2027
$-0.06 83.33%
Unlock
2028
$0.36 700.00%
Unlock
2029
$1.18 227.78%
Unlock
2030
$2.45 107.63%
Unlock
2031
$5.13 109.39%
Unlock
2032
$7.02 36.84%
Unlock

P/E ratio

Current -5.71 16.83%
2025
-4.45 22.03%
Unlock
2026
-6.44 44.72%
Unlock
2027
-38.24 493.79%
Unlock
2028
6.46 116.89%
Unlock
2029
1.98 69.35%
Unlock
2030
0.96 51.52%
Unlock
2031
0.46 52.08%
Unlock
2032
0.33 28.26%
Unlock

Based on analysts' sales estimates for 2025, the ImmunityBio Inc stock is valued at an EV/Sales of

26.55
Unlock
and an P/S ratio of
20.55
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 50.48 98.21%
2025
26.55 47.41%
Unlock
2026
12.65 52.36%
Unlock
2027
5.05 60.06%
Unlock
2028
2.84 43.82%
Unlock
2029
1.43 49.52%
Unlock
2030
0.82 42.99%
Unlock
2031
0.43 47.81%
Unlock
2032
0.30 28.98%
Unlock

P/S ratio

Current 39.08 98.27%
2025
20.55 47.41%
Unlock
2026
9.79 52.36%
Unlock
2027
3.91 60.06%
Unlock
2028
2.20 43.82%
Unlock
2029
1.11 49.52%
Unlock
2030
0.63 42.98%
Unlock
2031
0.33 47.82%
Unlock
2032
0.23 28.98%
Unlock

Current ImmunityBio Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
D. Boral Capital
Locked
Locked
Locked Aug 26 2025
D. Boral Capital
Locked
Locked
Locked Aug 19 2025
D. Boral Capital
Locked
Locked
Locked Aug 14 2025
D. Boral Capital
Locked
Locked
Locked Aug 05 2025
D. Boral Capital
Locked
Locked
Locked Jul 25 2025
D. Boral Capital
Locked
Locked
Locked Jul 08 2025
HC Wainwright & Co.
Locked
Locked
Locked Jun 04 2025
Analyst Rating Date
Locked
D. Boral Capital:
Locked
Locked
Aug 26 2025
Locked
D. Boral Capital:
Locked
Locked
Aug 19 2025
Locked
D. Boral Capital:
Locked
Locked
Aug 14 2025
Locked
D. Boral Capital:
Locked
Locked
Aug 05 2025
Locked
D. Boral Capital:
Locked
Locked
Jul 25 2025
Locked
D. Boral Capital:
Locked
Locked
Jul 08 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jun 04 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today